Predicting how pancreatic cancer responds to treatment before surgery
Improving response prediction to neoadjuvant therapy in pancreatic cancer
This study is looking to find out how different types of pancreatic tumors react to chemotherapy given before surgery, so we can better personalize treatment for patients and improve their outcomes.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10929448 on NIH RePORTER |
What this research studies
This research focuses on improving the prediction of how localized pancreatic cancer will respond to neoadjuvant chemotherapy, which is given before surgery. It aims to understand the molecular characteristics of pancreatic tumors that influence treatment response, particularly looking at different tumor subtypes. By analyzing patient samples and using advanced techniques like single-cell analysis, the research seeks to identify biomarkers that can help tailor treatment plans for better outcomes. Patients will be monitored over several months to assess their response to chemotherapy before surgical intervention.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with localized pancreatic cancer who are scheduled to receive neoadjuvant chemotherapy.
Not a fit: Patients with metastatic pancreatic cancer or those who are not candidates for chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in using molecular profiling to predict treatment responses in various cancers, suggesting that this approach may also be effective for pancreatic cancer.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Singh, Harshabad — Dana-Farber Cancer Inst
- Study coordinator: Singh, Harshabad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.